Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Disease-Free Survival"" wg kryterium: Temat


Tytuł:
2/1 dose schedule of sunitinib is superior than the 4/2 regimen for the first-line therapy of clear cell metastatic renal cell carcinoma - An Indian experience.
Autorzy:
Jaipuria J; Amity Centre for Cancer Epidemiology and Cancer Research, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.
Jain A; Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector - 5, New Delhi, India.
Gupta S; Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector - 5, New Delhi, India.
Sadasukhi N; Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector - 5, New Delhi, India.
Kasaraneni P; Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector - 5, New Delhi, India.
Singh A; Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector - 5, New Delhi, India.
Gupta K; Catalyst Clinical Services Pvt. Ltd., New Delhi, India.
Sharma G; Amity Centre for Cancer Epidemiology and Cancer Research, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.
Talwar V; Medical Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector - 5, New Delhi, India.
Rawal SK; Uro-Oncology Division, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Sector - 5, New Delhi, India.
Pokaż więcej
Źródło:
Indian journal of cancer [Indian J Cancer] 2023 Oct 01; Vol. 60 (4), pp. 493-500. Date of Electronic Publication: 2024 Jan 09.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Renal Cell*/pathology
Antineoplastic Agents*/adverse effects
Kidney Neoplasms*/pathology
Adult ; Humans ; Sunitinib/therapeutic use ; Indoles/adverse effects ; Pyrroles/adverse effects ; Treatment Outcome ; Disease-Free Survival ; Retrospective Studies
SCR Disease Name:
Clear-cell metastatic renal cell carcinoma
Czasopismo naukowe
Tytuł:
A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma.
Autorzy:
Ness DB; Department of Medicine and the Dartmouth Cancer Center at Dartmouth-Hitchcock Medical Center, Section of Clinical Pharmacology, Lebanon, New Hampshire, USA.
Pooler DB; Department of Medicine and the Dartmouth Cancer Center at Dartmouth-Hitchcock Medical Center, Section of Clinical Pharmacology, Lebanon, New Hampshire, USA.
Ades S; Division of Hematology/Oncology, University of Vermont Cancer Center, Burlington, Vermont, USA.
Highhouse BJ; Section of Hematology/Oncology and the Dartmouth Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Labrie BM; Department of Medicine and the Dartmouth Cancer Center at Dartmouth-Hitchcock Medical Center, Section of Clinical Pharmacology, Lebanon, New Hampshire, USA.
Zhou J; Department of Biomedical Data Science and the Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.
Gui J; Department of Biomedical Data Science and the Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.
Lewis LD; Department of Medicine and the Dartmouth Cancer Center at Dartmouth-Hitchcock Medical Center, Section of Clinical Pharmacology, Lebanon, New Hampshire, USA.; Section of Hematology/Oncology and the Dartmouth Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Ernstoff MS; Section of Hematology/Oncology and the Dartmouth Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.; Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis at National Cancer Institute, ImmunoOncology Branch, Bethesda, Maryland, USA.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Jun; Vol. 12 (12), pp. 13100-13110. Date of Electronic Publication: 2023 May 06.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Carcinoma, Renal Cell*/pathology
Kidney Neoplasms*/pathology
Humans ; Disease-Free Survival ; Pyrroles/therapeutic use ; Sirolimus/therapeutic use ; Sunitinib/therapeutic use
Czasopismo naukowe
Tytuł:
Preoperative Radio(Chemo)Therapy in Breast Cancer: Time to Switch the Perspective?
Autorzy:
Montero A; Department of Radiation Oncolo Gy, HM Sanchinarro University Hospital, HM Hospitales, 28050 Madrid, Spain.
Ciérvide R; Department of Radiation Oncolo Gy, HM Sanchinarro University Hospital, HM Hospitales, 28050 Madrid, Spain.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Dec 12; Vol. 29 (12), pp. 9767-9787. Date of Electronic Publication: 2022 Dec 12.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Antineoplastic Agents*/therapeutic use
Humans ; Female ; Neoadjuvant Therapy ; Combined Modality Therapy ; Disease-Free Survival
Czasopismo naukowe
Tytuł:
The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study.
Autorzy:
You L; Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3# East Qinchun Road, Hangzhou, 310016, Zhejiang, China.
Zheng X; Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3# East Qinchun Road, Hangzhou, 310016, Zhejiang, China.
Deng D; Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3# East Qinchun Road, Hangzhou, 310016, Zhejiang, China.; Laboratory of Cancer Biology, Key Laboratory of Biotherapy of Zhejiang Province, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Pan H; Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3# East Qinchun Road, Hangzhou, 310016, Zhejiang, China. .
Han W; Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3# East Qinchun Road, Hangzhou, 310016, Zhejiang, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Aug 26; Vol. 12 (1), pp. 14624. Date of Electronic Publication: 2022 Aug 26.
Typ publikacji:
Journal Article
MeSH Terms:
Angiogenesis Inhibitors*/therapeutic use
Antineoplastic Agents*/therapeutic use
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/pathology
Disease-Free Survival ; ErbB Receptors/genetics ; Exons ; Humans ; Liver Neoplasms/secondary ; Mutation ; Protein Kinase Inhibitors ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.
Autorzy:
Sun X; Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China.; Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhang Q; Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China.; Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Mei J; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
Yang Z; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
Chen M; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China. .
Liang T; Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China. .; Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Mar 19; Vol. 22 (1), pp. 293. Date of Electronic Publication: 2022 Mar 19.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*administration & dosage
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Phenylurea Compounds/*administration & dosage
Programmed Cell Death 1 Receptor/*administration & dosage
Quinolines/*administration & dosage
Adult ; Aged ; Carcinoma, Hepatocellular/pathology ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Liver Neoplasms/pathology ; Male ; Middle Aged ; Progression-Free Survival ; Retrospective Studies
Czasopismo naukowe
Tytuł:
A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study).
Autorzy:
Grünwald V; Interdisciplinary Genitourinary Oncology at the West-German Cancer Center, Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, University Hospital Essen, Essen, Germany.
Hilser T; Internal Medicine (Tumor Research) and Clinic for Urology, University Hospital Essen, Essen, Germany, .
Meiler J; Klinik Dr. Hancken GmbH, MVZ Oncology, Stade, Germany.
Goebell PJ; Clinic for Urology, University Hospital Erlangen, Erlangen, Germany.
Ivanyi P; Clinic for Hematology, Hemostasis, Oncology and Stemn Cell Transplantation, Medical School Hanover, Hanover, Germany.
Strauss A; Clinic for Urology, University Hospital Göttingen, Göttingen, Germany.
Hartmann A; Pathology, University Hospital Erlangen, Erlangen, Germany.
Bedke J; Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany.
Bergmann L; Medical Clinic 2, University Hospital Frankfurt, Frankfurt, Germany.
Pokaż więcej
Źródło:
Oncology research and treatment [Oncol Res Treat] 2022; Vol. 45 (5), pp. 272-280. Date of Electronic Publication: 2022 Jan 19.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Carcinoma, Renal Cell*/pathology
Kidney Neoplasms*/pathology
Axitinib/therapeutic use ; Bevacizumab/therapeutic use ; Disease-Free Survival ; Everolimus/therapeutic use ; Female ; Humans ; Interferons/therapeutic use ; Male ; Protein Kinase Inhibitors/therapeutic use ; Treatment Outcome ; Vascular Endothelial Growth Factor A
Czasopismo naukowe
Tytuł:
The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery.
Autorzy:
Jeong H; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Park KJ; Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Lee Y; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.; Department of Internal Medicine Division of Oncology, Haeundae Paik Hospital Cancer Center, Inje University College of Medicine, Busan, Korea.
Kim HD; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim JH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.; Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
Yoon S; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hong B; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Lee JL; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2022 Jan; Vol. 54 (1), pp. 226-233. Date of Electronic Publication: 2021 May 06.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*administration & dosage
Cisplatin/*administration & dosage
Neoadjuvant Therapy/*methods
Urinary Bladder Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Cystectomy/methods ; Disease-Free Survival ; Female ; Humans ; Lymphatic Metastasis/pathology ; Male ; Middle Aged ; Progression-Free Survival ; Urinary Bladder Neoplasms/pathology ; Urinary Bladder Neoplasms/surgery
Czasopismo naukowe
Tytuł:
Clinical Characteristics and Treatment Outcomes of Childhood Acute Promyelocytic Leukemia in Korea: A Nationwide Multicenter Retrospective Study by Korean Pediatric Oncology Study Group.
Autorzy:
Park KM; Department of Pediatrics, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
Yoo KH; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kim SK; Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Lee JW; Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Chung NG; Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Ju HY; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Koo HH; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lyu CJ; Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
Han SM; Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
Han JW; Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
Choi JY; Department of Pediatrics, Seoul National University Cancer Institute, Seoul National University College of Medicine, Seoul, Korea.
Hong KT; Department of Pediatrics, Seoul National University Cancer Institute, Seoul National University College of Medicine, Seoul, Korea.
Kang HJ; Department of Pediatrics, Seoul National University Cancer Institute, Seoul National University College of Medicine, Seoul, Korea.
Shin HY; Department of Pediatrics, Seoul National University Cancer Institute, Seoul National University College of Medicine, Seoul, Korea.
Im HJ; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
Koh KN; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
Kim H; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
Kook H; Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University medical school, Gwangju, Korea.
Baek HJ; Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University medical school, Gwangju, Korea.
Kim BR; Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University medical school, Gwangju, Korea.
Yang EJ; Department of Pediatrics, Pusan National University School of Medicines, Yangsan, Korea.
Lim JY; Department of Pediatrics, Gyeongsang National University College of Medicine, Jinju, Korea.
Park ES; Department of Pediatrics, Gyeongsang National University College of Medicine, Jinju, Korea.
Choi EJ; Department of Pediatrics, Daegu Catholic University School of Medicine, Daegu, Korea.
Park SK; Department of Pediatrics, University of Ulsan School of Medicine, Ulsan, Korea.
Lee JM; Department of Pediatrics, Yeungnam University College of Medicine, Daegu, Korea.
Shim YJ; Department of Pediatrics, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Korea.
Kim JY; Department of Pediatrics, School of Medicine, Kyungpook National University, Daegu, Korea.
Park JK; Department of Pediatrics, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
Kong SG; Department of Pediatrics, Kosin University of Medicine, Busan, Korea.
Choi YB; Departments of Pediatrics, Ajou University School of Medicine, Suwon, Korea.
Cho B; Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Lim YT; Department of Pediatrics, Pusan National University School of Medicines, Yangsan, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2022 Jan; Vol. 54 (1), pp. 269-276. Date of Electronic Publication: 2021 Apr 20.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Antineoplastic Agents/*administration & dosage
Leukemia, Promyelocytic, Acute/*drug therapy
Leukemia, Promyelocytic, Acute/*mortality
Tretinoin/*administration & dosage
Adolescent ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Child ; Child, Preschool ; Disease-Free Survival ; Female ; Humans ; Induction Chemotherapy/methods ; Infant ; Leukocyte Count ; Male ; Progression-Free Survival ; Remission Induction ; Republic of Korea/epidemiology ; Retrospective Studies ; Treatment Outcome ; Tretinoin/adverse effects
Czasopismo naukowe
Tytuł:
Second-Generation Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response: A Systematic Review and a Meta-Analysis.
Autorzy:
Di Q; Department of Hematology, First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Deng H; Department of Hematology, First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Zhao Y; Department of Hematology, First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Li BY; Department of Hematology, First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Qin L; Department of Hematology, First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Pokaż więcej
Źródło:
Computational and mathematical methods in medicine [Comput Math Methods Med] 2021 Dec 16; Vol. 2021, pp. 3110622. Date of Electronic Publication: 2021 Dec 16 (Print Publication: 2021).
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review; Retracted Publication
MeSH Terms:
Antineoplastic Agents/*administration & dosage
Leukemia, Myeloid, Chronic-Phase/*drug therapy
Protein Kinase Inhibitors/*administration & dosage
Computational Biology ; Dasatinib/administration & dosage ; Disease-Free Survival ; Duration of Therapy ; Female ; Humans ; Imatinib Mesylate/administration & dosage ; Male ; Pyrimidines/administration & dosage ; Recurrence ; Remission Induction
Czasopismo naukowe
Tytuł:
Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
Autorzy:
He M; Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Chi X; Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Shi X; Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Sun Y; Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Yang X; Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Wang L; Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Wang B; Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Li H; Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2021 Dec; Vol. 12 (23), pp. 3101-3109. Date of Electronic Publication: 2021 Nov 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*therapeutic use
L-Lactate Dehydrogenase/*blood
Lung Neoplasms/*drug therapy
Lung Neoplasms/*enzymology
Small Cell Lung Carcinoma/*drug therapy
Small Cell Lung Carcinoma/*enzymology
Aged ; Biomarkers, Tumor/blood ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Platinum ; Predictive Value of Tests ; Prognosis ; Retrospective Studies
Czasopismo naukowe
Tytuł:
A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer.
Autorzy:
Byeon S; Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea.
Kim H; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea.
Jeon HG; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Seo SI; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Jeon SS; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Lee HM; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Lee SI; Internal Medicine, Dankook University College of Medicine, Cheonan, Chungcheongnam-do, Korea.
Park SH; Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2021 Nov 29; Vol. 21 (1), pp. 1281. Date of Electronic Publication: 2021 Nov 29.
Typ publikacji:
Clinical Trial, Phase II; Journal Article
MeSH Terms:
Androgen Antagonists/*administration & dosage
Antineoplastic Agents/*administration & dosage
Docetaxel/*administration & dosage
Prostatic Neoplasms/*drug therapy
Aged ; Aged, 80 and over ; Androgen Antagonists/adverse effects ; Anemia/chemically induced ; Antineoplastic Agents/adverse effects ; Diarrhea/chemically induced ; Disease-Free Survival ; Docetaxel/adverse effects ; Drug Administration Schedule ; Fatigue/chemically induced ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Nail Diseases/chemically induced ; Neutropenia/chemically induced ; Pneumonia/chemically induced ; Prospective Studies ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/blood ; Prostatic Neoplasms, Castration-Resistant ; Stomatitis/chemically induced
Czasopismo naukowe
Tytuł:
Survival impact of additional chemotherapy after adjuvant concurrent chemoradiation in patients with early cervical cancer who underwent radical hysterectomy.
Autorzy:
Kim SI; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Kim JY; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Wee CW; Department of Radiation Oncology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, 20, Boramae-ro 5-gil, Dongjak-gu, Seoul, 07061, Republic of Korea.
Lee M; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Kim HS; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Chung HH; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Lee TS; Department of Obstetrics and Gynecology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, 20, Boramae-ro 5-gil, Dongjak-gu, Seoul, 07061, Republic of Korea.
Jeon HW; Department of Obstetrics and Gynecology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, 20, Boramae-ro 5-gil, Dongjak-gu, Seoul, 07061, Republic of Korea.
Park NH; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Song YS; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Kim TH; Department of Obstetrics and Gynecology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, 20, Boramae-ro 5-gil, Dongjak-gu, Seoul, 07061, Republic of Korea. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2021 Nov 22; Vol. 21 (1), pp. 1260. Date of Electronic Publication: 2021 Nov 22.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Chemoradiotherapy, Adjuvant*
Antineoplastic Agents/*therapeutic use
Hysterectomy/*methods
Uterine Cervical Neoplasms/*mortality
Uterine Cervical Neoplasms/*therapy
Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Case-Control Studies ; Disease-Free Survival ; Female ; Humans ; Lymph Node Excision ; Lymphatic Metastasis ; Middle Aged ; Pelvis ; Risk Factors ; Survival Analysis ; Uterine Cervical Neoplasms/pathology
Czasopismo naukowe
Tytuł:
Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations.
Autorzy:
Wilson BE; Princess Margaret Cancer Centre, Department of Medical Oncology, University of Toronto, Toronto, ON, Canada.; University of New South Wales, Kensington, NSW, Australia.
Desnoyers A; Princess Margaret Cancer Centre, Department of Medical Oncology, University of Toronto, Toronto, ON, Canada.
Nadler MB; Princess Margaret Cancer Centre, Department of Medical Oncology, University of Toronto, Toronto, ON, Canada.
Tibau A; Oncology Department, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau, and Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.
Amir E; Princess Margaret Cancer Centre, Department of Medical Oncology, University of Toronto, Toronto, ON, Canada.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2021 Aug; Vol. 10 (16), pp. 5405-5414. Date of Electronic Publication: 2021 Jul 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Drug Approval/*statistics & numerical data
Neoplasm Recurrence, Local/*epidemiology
Neoplasms/*drug therapy
Randomized Controlled Trials as Topic/*statistics & numerical data
Consent Forms/statistics & numerical data ; Disease-Free Survival ; Humans ; Kaplan-Meier Estimate ; Lost to Follow-Up ; Neoplasm Recurrence, Local/prevention & control ; Neoplasms/mortality ; Progression-Free Survival ; Randomized Controlled Trials as Topic/standards ; Sample Size ; Time Factors ; United States ; United States Food and Drug Administration/standards
Czasopismo naukowe
Tytuł:
A pharmacophore-based classification better predicts the outcomes of HER2-negative breast cancer patients receiving the anthracycline- and/or taxane-based neoadjuvant chemotherapy.
Autorzy:
Li X; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Sun H; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Liu Q; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Liu Y; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.
Hou Y; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Jin W; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2021 Jul; Vol. 10 (13), pp. 4658-4674. Date of Electronic Publication: 2021 Jun 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoadjuvant Therapy*
Receptor, ErbB-2*
Anthracyclines/*therapeutic use
Antineoplastic Agents/*therapeutic use
Breast Neoplasms/*drug therapy
Taxoids/*therapeutic use
Anthracyclines/chemistry ; Antineoplastic Agents/chemistry ; Breast Neoplasms/chemistry ; Breast Neoplasms/genetics ; Breast Neoplasms/mortality ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Female ; Gene Expression ; Humans ; Kaplan-Meier Estimate ; Nomograms ; Propensity Score ; Taxoids/chemistry
Czasopismo naukowe
Tytuł:
Real-World Study of Cisplatin, Etoposide, and Bleomycin Chemotherapy Regimen in Gestational Trophoblastic Neoplasia.
Autorzy:
Wang M; Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
Shen L; Department of Gynecologic and Obsterics, Shenzhen Sixth People's Hospital, Huazhong University of Science and Technology, Shenzhen, China.
Xu X; Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
Duan W; Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
Miao J; Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
Kong W; Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
Su L; Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
Wu Y; Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
Pokaż więcej
Źródło:
BioMed research international [Biomed Res Int] 2021 Jun 24; Vol. 2021, pp. 6661698. Date of Electronic Publication: 2021 Jun 24 (Print Publication: 2021).
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*pharmacology
Bleomycin/*administration & dosage
Cisplatin/*administration & dosage
Etoposide/*administration & dosage
Gestational Trophoblastic Disease/*drug therapy
Adult ; Disease-Free Survival ; Drug Resistance, Neoplasm ; Female ; Follow-Up Studies ; Gestational Trophoblastic Disease/pathology ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Pregnancy ; Pregnancy Complications ; Prognosis ; Prospective Studies ; Radiotherapy ; Remission Induction ; Retrospective Studies ; Salvage Therapy ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Pulmonary microinvasive small cell carcinoma with an extensive in-situ component identified after photodynamic therapy for 'squamous cell carcinoma in situ': a case report.
Autorzy:
Ota M; Department of Diagnostic Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Nakatani Y; Department of Pathology, Yokosuka Kyosai Hospital, Yokosuka, Japan.
Nakajima T; Department of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hiroshima K; Department of Pathology, Tokyo Women's Medical University, Yachiyo Medical Center, Yachiyo, Japan.
Motoi N; Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
Yoshino I; Department of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Ikeda JI; Department of Diagnostic Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Pokaż więcej
Źródło:
Histopathology [Histopathology] 2021 May; Vol. 78 (6), pp. 912-916. Date of Electronic Publication: 2021 Mar 05.
Typ publikacji:
Case Reports; Letter
MeSH Terms:
Photochemotherapy*
Antineoplastic Agents/*therapeutic use
Carcinoma in Situ/*diagnosis
Carcinoma, Squamous Cell/*drug therapy
Lung Neoplasms/*diagnosis
Small Cell Lung Carcinoma/*diagnosis
Aged ; Bronchoscopy ; Carcinoma in Situ/pathology ; Carcinoma in Situ/therapy ; Chemoradiotherapy, Adjuvant ; Cisplatin/therapeutic use ; Disease-Free Survival ; Etoposide/therapeutic use ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Male ; Small Cell Lung Carcinoma/drug therapy ; Small Cell Lung Carcinoma/pathology
Raport
Tytuł:
Second-line therapy in young patients with relapsed or refractory orbital rhabdomyosarcoma.
Autorzy:
Zloto O; Goldschleger Eye Institute, Sheba Medical Center, Affiliated with The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, PSL University, Paris, France.
Minard-Colin V; Pediatric Adolescent Young Adult Department, Institut de Cancérologie, Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
Boutroux H; Department of Pediatric Hematology and Oncology, Trousseau Hospital (AP-HP), Paris, France.
Brisse HJ; Imaging Department, Institut Curie, Paris, France.
Levy C; Ophthalmology Department, Institut Curie, Paris, France.
Kolb F; Plastic Surgery Department, Institut de Cancérologie, Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
Bolle S; Radiation Oncology Department, Institut de Cancérologie, Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
Carton M; Department of Biostatistics, Institut Curie, PSL University, Paris, France.
Helfre S; Radiotherapy Department, Institut Curie, Paris, France.
Orbach D; SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, PSL University, Paris, France.
Pokaż więcej
Źródło:
Acta ophthalmologica [Acta Ophthalmol] 2021 May; Vol. 99 (3), pp. 334-341. Date of Electronic Publication: 2020 Aug 24.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Neoplasm Recurrence, Local/*therapy
Orbital Neoplasms/*therapy
Radiotherapy/*methods
Rhabdomyosarcoma/*therapy
Adolescent ; Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Child ; Child, Preschool ; Combined Modality Therapy ; Disease-Free Survival ; Female ; Humans ; Infant ; Male ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Identifying gene expression patterns associated with drug-specific survival in cancer patients.
Autorzy:
Neary B; School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA.
Zhou J; School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA.
Qiu P; Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Mar 02; Vol. 11 (1), pp. 5004. Date of Electronic Publication: 2021 Mar 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Biomarkers, Tumor*/biosynthesis
Biomarkers, Tumor*/genetics
Databases, Nucleic Acid*
Gene Expression Regulation, Neoplastic*
Neoplasms*/drug therapy
Neoplasms*/genetics
Neoplasms*/metabolism
Neoplasms*/mortality
RNA-Seq*
Antineoplastic Agents/*administration & dosage
Disease-Free Survival ; Humans ; Survival Rate
Czasopismo naukowe
Tytuł:
Beta-blocker and survival in patients with lung cancer: A meta-analysis.
Autorzy:
Lei Z; Department of Respiratory and Critical Care Medicine, the Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
Yang W; Department of Respiratory and Critical Care Medicine, the Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
Zuo Y; Department of Endocrinology and Metabolism, the Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2021 Feb 16; Vol. 16 (2), pp. e0245773. Date of Electronic Publication: 2021 Feb 16 (Print Publication: 2021).
Typ publikacji:
Journal Article; Meta-Analysis
MeSH Terms:
Adrenergic beta-Antagonists/*therapeutic use
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Small Cell Lung Carcinoma/*drug therapy
Aged ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Observational Studies as Topic ; Retrospective Studies
Czasopismo naukowe
Tytuł:
A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Autorzy:
Heo JH; Genesis Research, LLC, Hoboken, NJ, USA.; The University of Texas at Austin, Austin, TX, USA.
Park C; Northeastern University, Boston, MA, USA.
Ghosh S; The University of Texas at Austin, Austin, TX, USA.
Park SK; College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea.
Zivkovic M; Genesis Research, LLC, Hoboken, NJ, USA.
Rascati KL; The University of Texas at Austin, Austin, TX, USA.
Pokaż więcej
Źródło:
Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2021 Feb; Vol. 46 (1), pp. 35-49. Date of Electronic Publication: 2020 Oct 28.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Anilides/*therapeutic use
Antineoplastic Agents/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Kidney Neoplasms/*drug therapy
Pyridines/*therapeutic use
Anilides/administration & dosage ; Carcinoma, Renal Cell/mortality ; Carcinoma, Renal Cell/secondary ; Disease-Free Survival ; Humans ; Kidney Neoplasms/mortality ; Kidney Neoplasms/pathology ; Neoplasm Metastasis ; Network Meta-Analysis ; Pyridines/administration & dosage
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies